Metabolically stable prodrugs

Abstract

Provided are prodrugs of various therapeutic agents that provide enhanced bioavailability of the therapeutic agent, and methods of treatment conditions in a subject by administration of the one or prodrugs. As provided herein a prodrug includes a therapeutic agent covalently attached to a cap, the cap having a structure according to formula (I) where: R1 is a branched or linear substituted or unsubstituted C2-C6 alkyl, alkenyl, or alkynl; X is —S(0)2-; R2 is a branched or linear substituted or unsubstituted C4-C20 alkyl, alkenyl, or alkynyl; and R3 is —H, C3-C5 cycloalkyl, C3-C5 cycloheteroalkyl, —C(CH3)3, —CF3, —C(CF3)3, or a substituted or unsubstituted phenyl.

Dependencies are inferred from the claim text.